Isofol Medical AB (publ) (ISOFOL.ST)
SEK 1.53
(-3.04%)
SEK 1.53
(-3.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.26 Million SEK | -76.48% |
| 2022 | 180.25 Million SEK | -20.55% |
| 2021 | 226.87 Million SEK | 1.46% |
| 2020 | 223.61 Million SEK | 33.26% |
| 2019 | 167.8 Million SEK | 86.76% |
| 2018 | 89.84 Million SEK | 23.78% |
| 2017 | 72.58 Million SEK | 13.39% |
| 2016 | 64.01 Million SEK | 57.34% |
| 2015 | 40.68 Million SEK | 0.0% |
| 2011 | 10.53 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.12 Million SEK | 25.2% |
| 2024 Q1 | 9.68 Million SEK | -4.5% |
| 2023 Q4 | 10.13 Million SEK | 34.37% |
| 2023 FY | 42.4 Million SEK | -76.48% |
| 2023 Q1 | 15.11 Million SEK | -44.9% |
| 2023 Q2 | 9.54 Million SEK | -36.88% |
| 2023 Q3 | 7.54 Million SEK | -20.94% |
| 2022 Q2 | 61.18 Million SEK | 14.25% |
| 2022 FY | 180.25 Million SEK | -20.55% |
| 2022 Q1 | 53.55 Million SEK | -20.74% |
| 2022 Q4 | 27.43 Million SEK | -27.96% |
| 2022 Q3 | 38.08 Million SEK | -37.75% |
| 2021 Q4 | 67.56 Million SEK | 17.79% |
| 2021 FY | 226.87 Million SEK | 1.46% |
| 2021 Q1 | 49.95 Million SEK | -26.98% |
| 2021 Q2 | 51.99 Million SEK | 4.09% |
| 2021 Q3 | 57.35 Million SEK | 10.31% |
| 2020 Q3 | 49.93 Million SEK | 5.72% |
| 2020 Q4 | 68.4 Million SEK | 36.98% |
| 2020 FY | 223.61 Million SEK | 33.26% |
| 2020 Q1 | 58.03 Million SEK | 4.62% |
| 2020 Q2 | 47.23 Million SEK | -18.6% |
| 2019 FY | 167.8 Million SEK | 86.76% |
| 2019 Q4 | 55.47 Million SEK | 21.51% |
| 2019 Q1 | 30.37 Million SEK | 5.1% |
| 2019 Q3 | 45.65 Million SEK | 25.71% |
| 2019 Q2 | 36.31 Million SEK | 19.57% |
| 2018 Q4 | 28.89 Million SEK | 71.0% |
| 2018 FY | 89.84 Million SEK | 23.78% |
| 2018 Q2 | 20.12 Million SEK | -15.88% |
| 2018 Q1 | 23.92 Million SEK | -6.58% |
| 2018 Q3 | 16.89 Million SEK | -16.05% |
| 2017 Q3 | 19.9 Million SEK | 45.14% |
| 2017 FY | 72.58 Million SEK | 13.39% |
| 2017 Q1 | 13.27 Million SEK | -56.55% |
| 2017 Q2 | 13.71 Million SEK | 3.32% |
| 2017 Q4 | 25.61 Million SEK | 28.68% |
| 2016 Q4 | 30.54 Million SEK | 249.19% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 64.01 Million SEK | 57.34% |
| 2016 Q2 | 10.68 Million SEK | 601455730235329600.0% |
| 2016 Q3 | 8.74 Million SEK | -18.13% |
| 2015 FY | 40.68 Million SEK | 0.0% |
| 2015 Q4 | 10.5 Million SEK | 0.0% |
| 2011 FY | 10.53 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NextCell Pharma AB | -576.01 Thousand SEK | 1361.764% |
| Biovica International AB (publ) | 133.72 Million SEK | 94.565% |
| Abliva AB (publ) | 27.86 Million SEK | 73.918% |
| Active Biotech AB (publ) | 44.8 Million SEK | 83.78% |
| Aptahem AB (publ) | 10.01 Million SEK | 27.414% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 97.633% |
| BioInvent International AB (publ) | 441.4 Million SEK | 98.353% |
| BioArctic AB (publ) | 89.62 Million SEK | 91.891% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 91.261% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.52% |
| Cantargia AB (publ) | 290.01 Million SEK | 97.494% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 66.805% |
| CombiGene AB (publ) | 44.14 Million SEK | 83.536% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 96.244% |
| Fluicell AB (publ) | 28.61 Million SEK | 74.603% |
| Genovis AB (publ.) | 88.19 Million SEK | 91.759% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 99.154% |
| Mendus AB (publ) | 129.13 Million SEK | 94.372% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -31.691% |
| LIDDS AB (publ) | 27.75 Million SEK | 73.811% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 58.898% |
| Saniona AB (publ) | 1.07 Million SEK | -574.838% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 63.274% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 82.952% |
| Xintela AB (publ) | 57.31 Million SEK | 87.319% |
| Amniotics AB (publ) | 29.07 Million SEK | 75.0% |
| Corline Biomedical AB | 30.16 Million SEK | 75.908% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 74.342% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 94.604% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 87.476% |
| Intervacc AB (publ) | 79.78 Million SEK | 90.891% |
| Kancera AB (publ) | 63.07 Million SEK | 88.478% |
| Lipum AB (publ) | 37.3 Million SEK | 80.518% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -0.193% |
| Nanologica AB (publ) | 69.88 Million SEK | 89.6% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 97.739% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 97.968% |
| AcouSort AB (publ) | 25.87 Million SEK | 71.912% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 94.917% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 93.355% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 94.652% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 55.686% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 96.001% |
| Simris Alg AB (publ) | 38.64 Million SEK | 81.191% |
| Ziccum AB (publ) | 27.87 Million SEK | 73.929% |
| SynAct Pharma AB | 224.49 Million SEK | 96.763% |
| OncoZenge AB (publ) | 15.9 Million SEK | 54.304% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.314% |
| 2cureX AB (publ) | 36.51 Million SEK | 80.097% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 50.399% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 69.659% |
| I-Tech AB | 40.14 Million SEK | 81.897% |
| Cyxone AB (publ) | 28.21 Million SEK | 74.24% |
| Biosergen AB | 26.8 Million SEK | 72.89% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 83.548% |
| Alzinova AB (publ) | 36.39 Million SEK | 80.031% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 97.492% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 93.684% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 7.488% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 93.447% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 50.558% |